DT120 Aces Second Phase 3 Trial, This Time for Anxiety
DFTX has more than doubled off its 52-week low of $8.7.
Summary
Definium's DT120 hit its primary endpoint in the Phase 3 Voyage study for generalized anxiety disorder, showing statistically significant and clinically meaningful improvement over placebo. This is the second positive late-stage readout for the drug, following the June 2026 EMERGE trial in major depressive disorder. No new safety signals emerged, and the CEO called the efficacy 'unprecedented,' suggesting a potential new standard of care. With $1.1 billion in cash as of Q2 2026, the company is well-funded to pursue regulatory submissions for both indications. The stock is trading near its 52-week high, reflecting high expectations now validated by this data. The drug is an LSD-based pill.
At the time of this announcement, DFTX was trading at $49.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $8.70 to $49.70. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.